AU2001230019A1 - Heparin with average molecular mass - Google Patents

Heparin with average molecular mass

Info

Publication number
AU2001230019A1
AU2001230019A1 AU2001230019A AU3001901A AU2001230019A1 AU 2001230019 A1 AU2001230019 A1 AU 2001230019A1 AU 2001230019 A AU2001230019 A AU 2001230019A AU 3001901 A AU3001901 A AU 3001901A AU 2001230019 A1 AU2001230019 A1 AU 2001230019A1
Authority
AU
Australia
Prior art keywords
heparin
average molecular
factor
activity
molecular mass
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001230019A
Inventor
Dieter Welzel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2001230019A1 publication Critical patent/AU2001230019A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Heparin (I) having an average molecular weight of 10-11.5 (preferably 10.5) kd is new. An independent claim is also included for the preparation of (I). ACTIVITY : Anticoagulant; thrombolytic; cardiant; antianginal. MECHANISM OF ACTION : Factor Xa antagonist; factor IIa antagonist; thrombin inhibitor. (I) has anti-Factor Xa activity 174.9 IU/mg and anti-Factor IIa activity 170.0 IU/mg, the corresponding values for Enoxoparin (RTM; low molecular heparin) being 100.0 IU/mg and 26.3 IU/mg and for Liquemin (RTM; un-fractionated heparin) 159.0 IU/mg and 159.0 IU/mg.
AU2001230019A 2000-01-10 2000-12-22 Heparin with average molecular mass Abandoned AU2001230019A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10000602 2000-01-10
DE10000602 2000-01-10
PCT/DE2000/004674 WO2001051525A1 (en) 2000-01-10 2000-12-22 Heparin with average molecular mass

Publications (1)

Publication Number Publication Date
AU2001230019A1 true AU2001230019A1 (en) 2001-07-24

Family

ID=7627036

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001230019A Abandoned AU2001230019A1 (en) 2000-01-10 2000-12-22 Heparin with average molecular mass

Country Status (9)

Country Link
US (1) US7008933B2 (en)
EP (2) EP1252194B1 (en)
AT (1) ATE279929T1 (en)
AU (1) AU2001230019A1 (en)
CA (1) CA2434393C (en)
DE (2) DE10084241D2 (en)
ES (1) ES2231303T3 (en)
RU (1) RU2322245C2 (en)
WO (1) WO2001051525A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2402753A1 (en) 2002-03-11 2012-01-04 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
WO2007140231A2 (en) * 2006-05-25 2007-12-06 Momenta Pharmaceutical, Inc. Low molecular weight heparin composition and uses thereof
US9139876B1 (en) * 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
WO2009105522A1 (en) * 2008-02-20 2009-08-27 Momenta Pharmaceuticals, Inc. Methods of making low molecular weight heparin compositions
US8435795B2 (en) * 2010-01-19 2013-05-07 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
WO2012115952A1 (en) 2011-02-21 2012-08-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
EP3348270A1 (en) * 2017-01-11 2018-07-18 Fytagoras B.V. Medium molecular weight heparin
EP3581189A1 (en) * 2018-06-14 2019-12-18 Fytagoras B.V. Medium molecular weight heparin for treatment and secondary prevention of ischemic stroke

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687765A (en) * 1983-07-25 1987-08-18 Choay S.A. Method and composition for thrombolytic treatment
CA2377734A1 (en) * 1999-06-30 2001-01-11 Hamilton Civic Hospitals Research Development, Inc. Heparin compositions that inhibit clot associated coagulation factors

Also Published As

Publication number Publication date
RU2322245C2 (en) 2008-04-20
EP1505079A3 (en) 2005-04-13
US20030134823A1 (en) 2003-07-17
EP1252194B1 (en) 2004-10-20
WO2001051525A1 (en) 2001-07-19
EP1252194A1 (en) 2002-10-30
ATE279929T1 (en) 2004-11-15
EP1505079A2 (en) 2005-02-09
CA2434393C (en) 2009-09-15
DE50008363D1 (en) 2004-11-25
ES2231303T3 (en) 2005-05-16
DE10084241D2 (en) 2003-02-20
CA2434393A1 (en) 2001-07-19
US7008933B2 (en) 2006-03-07
RU2003123505A (en) 2005-02-27

Similar Documents

Publication Publication Date Title
Hoffman et al. Cellular interactions in hemostasis
TW200722089A (en) New pharmaceutical compositions for treatment of thrombosis
AU3645697A (en) Amidinoindoles, amidinoazoles, and analogs thereof as inhibitors of factor xa and of thrombin
IL144032A0 (en) Serine protease inhibitors
EP2476728A3 (en) Low haze high strength polyethylene compositions
AU2001230019A1 (en) Heparin with average molecular mass
CY1112551T1 (en) Derivatives of partially released glycosaminoglycans as inhibitors of anti-angiogenic activity and activity
WO2000071493A3 (en) INHIBITORS OF FACTOR Xa
AU5497598A (en) Benzamidine derivatives
WO1995013385A3 (en) Thrombin mutants
NZ507835A (en) Heterocyclic derivatives which inhibit factor XA
ATE309693T1 (en) COMPOSITIONS CONTAINING LOW MOLECULAR WEIGHT HEPARIN
AU2002357972A1 (en) Heparin-containing ophthalmic agent
MXPA02000142A (en) Heparin compositions that inhibit clot associated coagulation factors.
ES2104598T3 (en) USE OF THE MODIFIED HEPARIN COFACTOR II.
EP0849280A3 (en) Fucans with low molecular weight having anticoagulant, antithrombinic and antithrombotic activity
EA200100966A1 (en) TREATMENT OF THROMBOSIS BY THE COMBINED APPLICATION OF THE INHIBITOR OF THE FACTOR Xa AND ASPIRIN, THE ACTIVATOR OF A TISSUE PLASMINOGEN (TPA), ANTAGONIST GPIIB / IIIA, A LOW-MOLECULAR HEPARIN OR HEPARIN
PT1294394E (en) ASSOCIATE PRODUCT UNDERSTANDING MELAGATRAN AND A FACTOR XA INHIBITOR
AU5682596A (en) Low molecular weight bicyclic-area type thrombin inhibitors
AU8211398A (en) Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits
Ofosu et al. Further studies on the mechanisms for the antithrombotic effects of sulfated polysaccharides in rabbits
EP1110556A4 (en) Preventives/remedies for multiple organ failure
Minnema et al. Effects of heparin therapy on fibrinolysis in patients with pulmonary embolism
Eisenberg Role of new anticoagulants as adjunctive therapy during thrombolysis
NO20030841L (en) A new specific mechanism for inhibition of platelet adhesion to collagen